Background illustration for clinical trials search

Paid Clinical Trials Portland

Discover 149 paid clinical trials in Portland, Maine. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.

Filter

Filter results

Results: 149

A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

for

Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8

Location: Portland ME, South Portland ME, Scarborough ME, Bath ME,

Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 5 - 60

Code: NCT05675410

Phase3, Recruiting

Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer

for

Castration Levels of Testosterone,

Location: Portland ME, Scarborough ME, Bath ME, Sanford ME,

Sponsor: SWOG Cancer Research Network

Sex: Male

Age: 18+

Code: NCT03678025

Phase3, Recruiting

Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer

for

Locally Advanced Lung Non-Small Cell Carcinoma,

Location: Portland ME, South Portland ME, Scarborough ME,

Sponsor: NRG Oncology

Sex: All

Age: 18+

Code: NCT05624996

Phase3, Recruiting

This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.

for

Non-Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung,

Location: Portland ME, Scarborough ME, South Portland ME,

Sponsor: Pfizer

Sex: All

Age: 18+

Code: NCT06758401

Phase3, Recruiting

Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG

for

Atrial Fibrillation, Stroke, Bleeding

Location: Portland ME, Boston MA, Lebanon NH, Burlington VT,

Sponsor: Icahn School of Medicine at Mount Sinai

Sex: All

Age: 18+

Code: NCT04045665

Phase3, Recruiting

MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles

for

Breast Cancer

Location: Portland ME, Albany NY, Waterbury CT, Mount Kisco NY,

Sponsor: Agendia

Sex: All

Age: 18+

Code: NCT03053193

Recruiting

(CIRRUS-2023-1) CLINICAL CLIN Assessment of PathFinder 1.0 on the CIRRUS 6000 and the CIRRUS 5000

for

Epiretinal Membrane, Dry Age Related Macular Degeneration,

Location: Portland ME, Kansas City MO, Fort Lauderdale FL,

Sponsor: Carl Zeiss Meditec-Dublin CoCe

Sex: All

Age: 18+

Code: NCT07680244

Recruiting

Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

for

Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8,

Location: South Portland ME, Scarborough ME, Augusta ME,

Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18+

Code: NCT06498635

Phase3, Recruiting

ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab

for

Anatomic Stage I Breast Cancer AJCC v8,

Location: South Portland ME, Brunswick ME, Sanford ME,

Sponsor: Alliance for Clinical Trials in Oncology

Sex: All

Age: 18+

Code: NCT06876714

Phase3, Recruiting

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

for

Advanced Malignant Solid Neoplasm,

Location: South Portland ME, Scarborough ME, Augusta ME,

Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 0+

Code: NCT05564377

Phase2, Recruiting

Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)

for

Recurrent Lung Non-Small Cell Carcinoma,

Location: South Portland ME, Brunswick ME, Sanford ME,

Sponsor: SWOG Cancer Research Network

Sex: All

Age: 18+

Code: NCT06616584

Phase2, Phase3, Recruiting

TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

for

Lymphoma, Non-Hodgkin, Multiple Myeloma, Advanced Solid Tumors

Location: South Portland ME, Scarborough ME, Biddeford ME,

Sponsor: American Society of Clinical Oncology

Sex: All

Age: 12+

Code: NCT02693535

Phase2, Recruiting

Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer

for

Renal Pelvis and Ureter Urothelial Carcinoma

Location: South Portland ME, Scarborough ME, Sanford ME,

Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18+

Code: NCT04628767

Phase2, Phase3, Recruiting

Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics

for

Breast Carcinoma, Colorectal Carcinoma,

Location: South Portland ME, Scarborough ME, Biddeford ME,

Sponsor: Wake Forest University Health Sciences

Sex: All

Age: 18+

Code: NCT06418204

Recruiting

Zanubrutinib and Venetoclax in CLL (ZANU-VEN)

for

Chronic Lymphocytic Leukemia (CLL),

Location: Scarborough ME, Boston MA, South Weymouth MA

Sponsor: Dana-Farber Cancer Institute

Sex: All

Age: 18+

Code: NCT05168930

Phase2, Recruiting

A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)

for

Renal Cell Carcinoma

Location: Westbrook ME, Baltimore MD, Charlotte NC, Knoxville TN,

Sponsor: Merck Sharp & Dohme LLC

Sex: All

Age: 18+

Code: NCT07227402

Phase3, Recruiting

Fixed Duration Pirtobrutinib and Obinutuzumab in Chronic Lymphocytic Leukemia

for

Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma

Location: Scarborough ME, Boston MA

Sponsor: Inhye Ahn

Sex: All

Age: 18+

Code: NCT06333262

Phase2, Recruiting

A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer

for

HER2-positive Breast Cancer, Breast Cancer

Location: Scarborough ME, New York NY, Camillus NY,

Sponsor: Jazz Pharmaceuticals

Sex: All

Age: 18+

Code: NCT07102381

Phase2, Recruiting

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)

for

Triple Negative Breast Cancer

Location: Scarborough ME, Methuen MA, Boston MA,

Sponsor: Gilead Sciences

Sex: All

Age: 18+

Code: NCT05633654

Phase3, Recruiting

ATEMPT 2.0: Adjuvant T-DM1 vs TH

for

Breast Cancer, HER2-positive Breast Cancer

Location: Scarborough ME, Portsmouth NH, Concord NH,

Sponsor: Dana-Farber Cancer Institute

Sex: All

Age: 18+

Code: NCT04893109

Phase2, Recruiting

Paid Clinical Trials Portland

Filter results

A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer

Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer

This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.

Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG

Interested in new trials?

MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles

(CIRRUS-2023-1) CLINICAL CLIN Assessment of PathFinder 1.0 on the CIRRUS 6000 and the CIRRUS 5000

Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)

TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer

Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics

Zanubrutinib and Venetoclax in CLL (ZANU-VEN)

A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)

Fixed Duration Pirtobrutinib and Obinutuzumab in Chronic Lymphocytic Leukemia

A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)

ATEMPT 2.0: Adjuvant T-DM1 vs TH